Massachusetts Institute of Technology

Vertex Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Therics, Inc.

Michael J. Cima

Wendy E. Pryce Lewis

Charles William Rowe

Peter A. Materna

Michael John Cima

Peter A Materna

Wendy E Pryce Lewis

Winston C Tse

Dimitrios Stefanidis

Christopher Young

John O Link

Michael Graupe

Sandeep Kumar

Jennifer R Zhang

Scott D Schroeder

Jaedeok Yoo

Roland D Saito

Donald C Monkhouse

Eric Gorman

Anna Chiu

Michael J Cima

Stephen R Yant

Dana J Levine

Steven J Henry

Christopher R Young

Laura Elizabeth Bauer

Andrew Stephen Mulato

Martin Sunkwang Rhee

Scott P Sellers

The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.

Capsid inhibitors for the treatment of HIV

The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

Therapeutic compounds

A uniaxially compressed dosage form manufactured by three-dimensional printing that preserves the predetermined internal architecture of the dosage form while producing an improved surface finish. The compression compacts the dosage form, eliminating at least some of the void space that remains at the end of conventional three-dimensional printing. Surface finish obtained as a result of the uniaxial compression process can be essentially equal to that obtained from conventional tablet pressing. Additionally, the internal structure or spatial variation of composition of the dosage form is preserved during the pressing operation, with geometric shrinkage occurring mostly in the direction of the axis of pressing. Further, as a result of compression, a greater quantity of API can be packed into a given final volume of dosage form.

System and method for uniaxial compression of an article, such as a three dimensionally printed dosage form

Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein.

Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

System and method for uniaxial compression of an article, such as a three-dimensionally printed dosage form

The present invention includes controlled release dosage forms and methods of designing and manufacturing dosage forms to obtain specific release profiles, for example, zero-order release profiles, escalating release profiles or decreasing release profiles. The dosage forms of the present invention can include spatial variation of API concentration in the dosage form and can include nested regions. Dosage forms according to the present invention may be manufactured by any appropriate method for obtaining the internal structure as disclosed herein for producing zero-order release profiles and increasing or decreasing release profiles. The invention further includes methods of manufacturing such dosage forms, such as by three-dimensional printing, possibly also including compression of the dosage form after three-dimensional printing. The invention further includes methods of designing such dosage forms. Release profiles from non-uniform distributions of API concentration may be predicted based on simple experiments with uniform-concentration dosage forms.

System for manufacturing controlled release dosage forms, such as zero-order release profile dosage form manufactured by three-dimensional printing

Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing

A fabrication method to rapidly fabricate different prototypes of drug delivery systems, medical devices, pharmaceutical dosage forms, tissue scaffolds or other bioaffecting agents in small batches or individual forms using a computer-guided system to vary the composition and structure in order to optimize the product and the manufacturing process. The process is immediately scalable. An Expert System can be used with the method to recommend different compositions and designs of the prototypes, devices, dosage forms, tissue scaffold or other bioaffecting agents.

Rapid prototyping and manufacturing process

Growing community of inventors

Medford, MA, United States of America

Charles William Rowe